Startup profile · funding coverage
Vumedi funding, valuation and investors
Physician video and podcast learning platform using AI to retrieve real clinical practice; backed by Oak HC/FT.
Verified company research · funding, investors and latest developments
Keep track of Vumedi
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B disclosed; investment completed earlier, exact closing date unknown
$104M (company/lead-investor reported; not $140M) · November 10, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$104M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Oakland, California, United States
Investors in latest funding
Lead: Oak HC/FT
Overview
Vumedi (Oakland, California) hosts expert videos and podcasts for clinician education. Its Nov 10 2026 announcement describes expanded AI search funded by a $104M Series B growth investment from Oak HC/FT that had already been used for talent, R&D and products. The exact legal close date, valuation and any other investors are unreported. Both the issuer press release and Oak HC/FT original investor essay explicitly state $104M.
Secondary $140M reporting is not supported by these two primary sources. A May 2025 SEC Form D for about $79.98M sold in exempt securities is not proven to be another round or identical to this Series B and is not added. The product draws on 100,000+ physician-led videos and nearly 5,000 podcasts in over 21 specialties.
The issuer says 150,000+ NPI-verified clinicians used AI functions with over 1 million interactions and 56M minutes of platform engagement over twelve months. These are company claims, not verified paid customers, ARR, clinical outcomes or randomized performance studies. The 3.5x greater time spent and 122% more video watched among AI users compared with non-AI users reflect observational comparison, not AI causal effect.
Why Vumedi is interesting
The company and Oak HC/FT both establish an already-invested $104M Series B, contradicting secondary $140M claims; the disclosure on November 10 does not establish a new November close.
Product & use cases
Illustrative physician journey: (1) sign in as a verified clinician, (2) ask about clinical evidence or a challenging procedure, (3) receive synthesis of relevant specialists' positions, (4) open cited timestamp in original physician-led video/podcast and inspect context, (5) validate against current clinical guidelines and patient-specific circumstances. Vumedi serves clinicians and life-sciences organizations using educational content and marketing; verified advertising rates and physician subscription pricing are undisclosed. It is not a diagnostic device or substitute for clinician judgment.
- Surgeon reviews time-stamped peer procedure technique alongside clinical guidelines.
- Physician compares expert treatment-sequencing discussion before making an independent decision.
- Life-sciences advertiser considers sponsored clinical education, subject to privacy and promotional standards.
Key facts
- November 10 company release and lead investor memo: $104M Series B ALREADY invested; no evidence of new November cash closing.
- 150,000+ NPI-verified clinicians used AI, issuer-reported, not paying members.
- 100,000+ clinician videos, nearly 5,000 podcasts; timestamp-linked original medical content.
- Engagement claims 3.5x and +122% are selection-biased observational comparisons, not clinical outcomes.
- May 2025 Form D for approximately $80M does not prove a second round; $140M secondary reports conflict with $104M primary disclosures.
Funding history (newest first)
Series B disclosed; investment completed earlier, exact closing date unknown
2026-11-10 $104M (company/lead-investor reported; not $140M)- Oak HC/FT (lead)
Source: Read source · businesswire.com
Competitive landscape
Edge: Video-first expert perspective search and verifiable source timestamps contrast with article-first clinical LLMs; content quality, conflict of interest and accuracy remain unvalidated.
Diligence gaps: whether physician access is paid; sponsor contracts and commercial terms; independent proof of clinical accuracy or patient outcomes; selection and editorial independence of featured experts; sponsored-content conflicts; handling of health/professional data; potential selection bias in platform engagement. FDA/medical professional regulation and advertising rules may apply depending on functionality; no claim of cleared clinical decision support. A 2025 Form D cannot be identified as a new or additional round without confirmation.
-
OpenEvidence adjacent
Literature-centered clinical AI search.
-
Doximity clinical AI adjacent
Physician workflow AI and communications tools.
-
PubMed and specialty clinical guidelines alternative
Published evidence and authoritative standards, essential for corroboration.
-
Medscape incumbent
Established clinician educational material.
Notable stories
- Issuer announcement November 10, 2026: businesswire.com (external source)
- Oak HC/FT investment thesis same day: oakhcft.com (external source)
- SEC May 2025 Form D source, not established as separately additive: sec.gov (external source)
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Vumedi
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.